Leanne G. Ahronian

TL;DR: The first genetic mechanisms of clinical acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive ICC are reported, which can inform future strategies for detecting resistance mechanisms and inducing more durable remissions in ICC and in the wide variety of cancers where the FGFR pathway is being explored as a therapeutic target.

TL;DR: In this article, the authors studied EGFR blockade in colorectal cancer to assess whether tissue and liquid biopsies can be integrated with radiological imaging to monitor the impact of individual oncogenic alterations on lesion-specific responses.

TL;DR: Initial characterization of clinical acquired resistance mechanisms to combined RAF/EGFR or RAF/MEK combinations identified several MAPK pathway alterations driving resistance by reactivating MAPK signaling, highlighting the critical dependence of BRAF-mutant colorectal cancers onMAPK signaling and offering potential strategies to overcome resistance.

TL;DR: This study provides one of the first examples of how large-scale genomic profiling of cfDNA from patients with colorectal cancer can detect genomic alterations at frequencies comparable to those observed by direct tumor sequencing.

TL;DR: This article found that 40-50% of MET-amplified esophagogastric cancer patients harbor coamplification of HER2 and/or EGFR concurrently in the same tumor cells, which can drive de novo resistance.